Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Recurrent Breast Carcinoma|Stage IV Breast Cancer
Interventions: BIOLOGICAL: Bevacizumab|DRUG: Erlotinib Hydrochloride|OTHER: Laboratory Biomarker Analysis
Sponsor: National Cancer Institute (NCI)